Přehled o publikaci
2023
Exploring the mechanisms of Venetoclax resistence via drug screening and genome-wide CRISPR screening.
LADUNGOVÁ, Adriana; Helena PESCHELOVÁ; Lenka DOSTÁLOVÁ; Yusuf LODHI; Narendra Varma GOTTUMUKKALA et al.Základní údaje
Originální název
Exploring the mechanisms of Venetoclax resistence via drug screening and genome-wide CRISPR screening.
Autoři
LADUNGOVÁ, Adriana; Helena PESCHELOVÁ; Lenka DOSTÁLOVÁ; Yusuf LODHI; Narendra Varma GOTTUMUKKALA; Jiří MAYER a Michal ŠMÍDA
Vydání
The 65th ASH Annual Meeting and Exposition, San Diego, California, USA in Blood, 2023
Další údaje
Jazyk
angličtina
Typ výsledku
Konferenční abstrakta
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Označené pro přenos do RIV
Ne
Organizace
Středoevropský technologický institut – Masarykova univerzita – Repozitář
Klíčová slova anglicky
BCL-2 inhibitor; acute myeloid leukemia; MCL1 upregulation
Návaznosti
MUNI/A/1330/2021, interní kód Repo. MUNI/A/1419/2021, interní kód Repo.
Změněno: 6. 1. 2026 00:51, RNDr. Daniel Jakubík
Anotace
V originále
Combining Venetoclax, a selective BCL-2 inhibitor, with hypomethylating agents has revolutionized frontline acute myeloid leukemia (AML) treatment. Despite its success, the occurrence of resistance remains a significant concern, limiting the range of available treatment alternatives. Little is known about the mechanism by which the cells escape the treatment. Recent studies have observed MCL1 upregulation in AML cells to promote resistance, and the rationale to use an MCL1 inhibitor became attractive. Although MCL1 inhibitors work exceptionally well in vitro their clinical trials were unsuccessful due to their toxicity. Here, we aim to identify other genes responsible for acquiring resistance and tackle the problem through screening for clinically approved drugs to rapidly benefit the patients with our study.
